Dyslipidemia has long been recognized as a major risk factor for cardiovascular diseases, primarily because of its role in the pathophysiology of large- and medium-sized atherosclerosis.[16] A growing scientific consensus suggests that dyslipidemia may lead to microvascular dysfunction before manifesting as overt atherosclerosis.[17] In line with this, our study demonstrated abnormal lipid metabolism indices among patients with CSFP, including increased total cholesterol, decreased apoE, and significantly elevated plasma FFA concentrations (P < .01). This evidence concerns the gene APOE and metabolic syndrome.